Mathew Garnett, PhD
Senior Group Leader
Wellcome Sanger Institute
Functional Genomics for Cancer Drug Discovery
The next-generation sequencing of tumours is providing an increasingly detailed description of the molecular alterations that occur across the diversity of human cancers. An important and challenging next step is to convert this wealth of information into new therapeutic hypothesises to guide patient care. My laboratory integrates cancer genomics, experimental functional genomics and mechanistic studies to elucidate vulnerabilities operative in cancer cells. In my presentation, I will discuss recent results from my laboratory applying CRISPR-based technologies and how these are shaping our understanding of the landscape of targetable dependencies in cancer cells and informing drug discovery efforts.
